Amicus Therapeutics, Inc. (0HF9.L)
0HF9.L Stock Price Chart
Explore Amicus Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0HF9.L price movements and trends.
0HF9.L Company Profile
Discover essential business fundamentals and corporate details for Amicus Therapeutics, Inc. (0HF9.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
499.00
Website
https://amicusrx.comCEO
Bradley L. Campbell
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
0HF9.L Financial Timeline
Browse a chronological timeline of Amicus Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $147.49M.
Earnings released on 1 May 2025
EPS came in at -$0.07 falling short of the estimated -$0.05 by -29.06%, while revenue for the quarter reached $125.25M, missing expectations by -15.08%.
Earnings released on 19 Feb 2025
EPS came in at $0.05 surpassing the estimated $0.01 by +295.90%, while revenue for the quarter reached $149.71M, beating expectations by +8.85%.
Earnings released on 6 Nov 2024
EPS came in at -$0.02 falling short of the estimated $0.00 by -1.97K%, while revenue for the quarter reached $141.52M, missing expectations by -3.97%.
Earnings released on 8 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.05 by +5.88%, while revenue for the quarter reached $126.67M, beating expectations by +4.50%.
Earnings released on 9 May 2024
EPS came in at -$0.16 falling short of the estimated -$0.06 by -148.25%, while revenue for the quarter reached $110.40M, missing expectations by -0.70%.
Earnings released on 11 Mar 2024
EPS came in at -$0.12 falling short of the estimated -$0.06 by -99.36%, while revenue for the quarter reached $115.08M, beating expectations by +0.64%.
Earnings released on 8 Nov 2023
EPS came in at -$0.07 surpassing the estimated -$0.08 by +3.87%, while revenue for the quarter reached $103.50M, beating expectations by +1.18%.
Earnings released on 8 Aug 2023
EPS came in at -$0.15 falling short of the estimated -$0.11 by -29.59%, while revenue for the quarter reached $94.50M, beating expectations by +5.20%.
Earnings released on 10 May 2023
EPS came in at -$0.18 falling short of the estimated -$0.14 by -32.78%, while revenue for the quarter reached $86.27M, beating expectations by +3.71%.
Earnings released on 1 Mar 2023
EPS came in at -$0.20 falling short of the estimated -$0.12 by -69.56%, while revenue for the quarter reached $88.10M, beating expectations by +2.07%.
Earnings released on 30 Sept 2022
EPS came in at -$0.12 surpassing the estimated -$0.19 by +39.01%, while revenue for the quarter reached $81.69M, missing expectations by -2.99%.
Earnings released on 30 Jun 2022
EPS came in at -$0.21 falling short of the estimated -$0.21 by -0.96%, while revenue for the quarter reached $80.73M, missing expectations by -5.98%.
Earnings released on 31 Mar 2022
EPS came in at -$0.30 falling short of the estimated -$0.25 by -16.05%, while revenue for the quarter reached $78.72M, beating expectations by +1.98%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$0.30, while revenue for the quarter reached $82.15M.
Earnings released on 30 Sept 2021
EPS came in at -$0.19 falling short of the estimated -$0.16 by -20.25%, while revenue for the quarter reached $79.55M, missing expectations by -4.63%.
Earnings released on 30 Jun 2021
EPS came in at -$0.19, while revenue for the quarter reached $77.41M.
Earnings released on 31 Mar 2021
EPS came in at -$0.25, while revenue for the quarter reached $66.40M.
Earnings released on 31 Dec 2020
EPS came in at -$0.27, while revenue for the quarter reached $70.57M.
Earnings released on 30 Sept 2020
EPS came in at -$0.25, while revenue for the quarter reached $67.44M.
0HF9.L Stock Performance
Access detailed 0HF9.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.